Mainz Biomed NV 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

31 Mar 2026

MYNZ

10-K: Mainz Biomed pivots, plans massive recap

Mainz Biomed slashes legacy cancer programs, sells ColoAlert IP, lines up $6M preferred financing that could exceed 95% dilution, and seeks shareholder approval to rebrand as Quantum Cyber N.V.